Seat No.:	Enrolment No.

Subject code: 910106

GUJARAT TECHNOLOGICAL UNIVERSITY M. PHARM. - SEMESTER – I • EXAMINATION – WINTER 2012

Date: 09/01/2013

•		me: Clinical Pharmacy Practice) am - 01.30 pm Total Marks	s: 80
Instr	2. Ma	IS: tempt any five questions. ake suitable assumptions wherever necessary. gures to the right indicate full marks.	
Q.1	(a) (b)	Write a note on development and scope of clinical pharmacy. Explain the various tests performed to verify hepatic function and write a note on drug induced hepatotoxicity.	06 05
	(c)	Discuss the importance of various hematological parameters.	05
Q.2	(a)	Explain the importance of reviewing drug utilization by patient. How can it be done?	06
	(b) (c)	What is pharmacovigilance? Discuss the role of pharmacist in it. Which factors are considered while analyzing the patient data for case presentation?	05 05
Q.3	(a)	What are the goals of clinical pharmacist for participation in ward round? What preparation should be done by clinical pharmacist for successful round?	06
	(b)	Write a note on pulmonary function tests and their significance.	05
	(c)	What are the duties and responsibilities of clinical pharmacist in ADR reporting? Give sample formats of ADR reports.	05
Q.4	(a)	Discuss patient counseling techniques.	06
	(b)	Discuss the reasons and hazards of self medication.	05
	(c)	Describe essential drugs. Explain the reason for irrational drug use.	05
(t	(a)	Explain Naranjo's and WHO causality assessment scale.	06
	(b)	Explain direct and indirect costs with examples.	05
	(c)	Explain- formation and importance of Essential Drug list.	05
Q. 6	(a)	Explain the need for pharmacoeconomic evaluations. Write a short note on cost-minimization evaluation.	06
	(b)	Describe how to achieve quality assurance in pharmacy practice.	05
	(c)	Compare between primary, secondary and tertiary literature available for review.	05
Q.7 (a) (b) (c)	(a)	What are the various markers of ischemic heart injury? How their levels change during ischemic injury?	06
	(b)	Write a note on Pharmaceutical care concept.	05
	(c)	Explain measures for minimizing clinically relevant drug interactions.	05
